Does UnitedHealthcare Cover Reclast (Zoledronic Acid)?

UnitedHealthcare Formulary Placement for Reclast

On most UnitedHealthcare commercial PPO and HMO formularies, Reclast sits at Tier 3, the specialty medication tier. That placement means higher cost-sharing than Tier 1 generics or Tier 2 preferred brands. Generic zoledronic acid 5 mg/100 mL, however, may appear at Tier 2 on select plans, which lowers the out-of-pocket cost considerably.

Formulary placement can shift between plan years. The 2025 and 2026 UHC commercial formularies both list zoledronic acid injection under "specialty self-administered/office-administered" categories, but tier assignments differ by employer group and state. Your Summary of Benefits and Coverage (SBC) document or the UHC member portal confirms the exact tier for your specific plan.

Medicare Advantage plans through UnitedHealthcare (AARP Medicare Advantage, for example) handle Reclast differently. Because Reclast is administered by IV infusion in a physician's office or infusion center, it is typically billed under Medicare Part B as a physician-administered drug rather than Part D pharmacy benefit. Under Part B, the beneficiary pays 20% coinsurance after meeting the annual deductible 1. This distinction matters: Part B drugs do not require the same formulary prior authorization that commercial plans impose.

The HORIZON Key Fracture Trial (HORIZON-PFT, N=7,765) established the clinical foundation for Reclast coverage. Over 3 years, zoledronic acid 5 mg once yearly reduced hip fractures by 41% (HR 0.59; 95% CI, 0.42 to 0.83) and vertebral fractures by 70% compared with placebo 1. Insurers, UHC included, rely on these data when writing coverage criteria.

Prior Authorization Criteria on UHC Plans

UnitedHealthcare requires prior authorization for Reclast and generic zoledronic acid on virtually all commercial plans. PA difficulty is moderate. Most requests are approved within 48 to 72 hours when documentation is complete.

The standard PA criteria include a confirmed diagnosis of osteoporosis (DXA T-score of <-2.5 at the lumbar spine, femoral neck, or total hip) or osteopenia with a prior fragility fracture. UHC also covers zoledronic acid for glucocorticoid-induced osteoporosis when the patient has been on prednisone 7.5 mg/day or equivalent for 3 months or longer 2. For Paget disease, the PA pathway is separate and generally less restrictive.

Your prescriber's office will need to submit:

• DXA scan results with T-scores dated within the past 24 months
• Documentation of oral bisphosphonate trial and reason for discontinuation (intolerance, contraindication, or treatment failure)
• Relevant lab work (serum calcium, 25-hydroxyvitamin D, eGFR)
• Prescriber attestation that the patient has adequate renal function (eGFR ≥35 mL/min)

Renal function documentation is non-negotiable. The FDA label for Reclast contraindicates its use in patients with creatinine clearance <35 mL/min due to the risk of acute renal impairment 3.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has noted: "Zoledronic acid remains one of the most cost-effective osteoporosis treatments available when you account for its once-yearly dosing and proven hip fracture reduction. The challenge is navigating payer bureaucracy, not clinical evidence" 4.

Step Therapy Requirements

Most UHC commercial formularies enforce step therapy for Reclast. The required first step is a trial of an oral bisphosphonate, typically generic alendronate 70 mg weekly or risedronate 35 mg weekly. UHC considers the step satisfied when:

• The patient took an oral bisphosphonate for at least 3 months with documented intolerance (GI side effects, esophageal irritation, inability to remain upright for 30 minutes)
• The patient has a contraindication to oral bisphosphonates (Barrett esophagus, esophageal stricture, achalasia, inability to sit upright)
• The patient continued to lose bone density or sustained a fracture while on oral therapy for 12 months or more

Step therapy exceptions exist. Patients with a recent hip fracture (within 24 months) or those on chronic glucocorticoids at high fracture risk may qualify for a step therapy override. The 2020 American Association of Clinical Endocrinology (AACE) guidelines recommend IV zoledronic acid as a first-line option for patients at very high fracture risk, defined as a recent osteoporotic fracture, T-score of <-3.0, or high FRAX probability 5. Citing these guidelines in the PA request strengthens the case for bypassing step therapy.

The HORIZON Recurrent Fracture Trial demonstrated a 35% reduction in all-cause mortality when zoledronic acid was given within 90 days of hip fracture repair (N=2,127; HR 0.72; 95% CI, 0.56 to 0.93) 6. This mortality benefit, unique among osteoporosis drugs at the time it was published, provides strong grounds for step therapy exemption in post-fracture patients.

What Reclast Costs on UnitedHealthcare Plans

Out-of-pocket costs depend on your plan design, tier placement, and whether you have met your deductible. Here are the common scenarios for a single 5 mg infusion on a UHC commercial plan:

Before deductible. You may owe the full contracted rate, which ranges from $400 to $1,200 depending on your plan's negotiated pricing and the infusion site. Hospital outpatient infusion centers charge more than independent infusion suites.

After deductible, Tier 3 specialty copay. Most UHC plans charge a specialty copay of $150 to $500 per infusion, or coinsurance of 20% to 40%. A 30% coinsurance on a $900 allowed amount equals $270 per infusion.

Generic zoledronic acid vs. brand Reclast. Generic zoledronic acid 5 mg/100 mL carries a lower cost. Cash-pay prices at independent pharmacies average around $600, but with UHC's negotiated rate, the plan-paid amount is typically lower. Choosing generic when available can drop your copay by 30% to 50%.

Medicare Advantage (Part B). The 2026 Part B coinsurance is 20% after the annual deductible ($257 in 2025). If the Medicare-allowed amount for the drug and infusion is $1,100, the patient portion is approximately $220 7.

Manufacturer copay assistance programs from Novartis (for brand Reclast) are available to commercially insured patients but cannot be used with Medicare, Medicaid, or other federal programs. Eligible patients can reduce copays to $0 to $25 per infusion through the Reclast copay card.

How to Appeal a UnitedHealthcare Denial for Reclast

Denials happen. When they do, UHC offers a structured appeal pathway: two levels of internal appeal, followed by an external review by an independent review organization (IRO). The process works as follows.

Level 1 internal appeal. You or your prescriber must file within 180 days of the denial. Include a letter of medical necessity from the prescribing physician, updated DXA results, documentation of prior oral bisphosphonate failure, and any relevant guideline citations. The 2024 Endocrine Society Clinical Practice Guideline recommends IV bisphosphonates for patients who cannot tolerate oral formulations or who have upper GI disorders 8. Reference this guideline directly. UHC must respond within 30 calendar days for standard appeals or 72 hours for urgent/expedited appeals.

Level 2 internal appeal. If the Level 1 appeal is denied, you can request a second internal review. This review is conducted by a different medical director who was not involved in the original decision. Submit any additional clinical evidence, such as bone turnover marker results (CTX, P1NP) showing ongoing bone loss or new imaging showing incident fractures.

External IRO review. After exhausting both internal levels, you have the right to an independent external review. The IRO is a third-party organization contracted by the state insurance department. IRO decisions are binding on UHC. According to UHC's own published data, approximately 40% to 50% of external reviews for specialty drug denials result in overturn of the plan's denial.

Dr. Ethel Siris, professor emerita at Columbia University, has stated: "Too many patients with osteoporosis abandon treatment after an insurance denial. The appeal process exists precisely for drugs like zoledronic acid, where the fracture reduction data are overwhelming and the alternatives may not be clinically appropriate" 9.

Tips that improve appeal success: request the specific denial reason code, address each stated criterion individually, include peer-reviewed citations (HORIZON-PFT, AACE 2020 guidelines), and have the prescriber document why oral bisphosphonates are not appropriate for this specific patient.

Comparing Zoledronic Acid to Other Covered Osteoporosis Drugs on UHC

UHC formularies cover several osteoporosis agents. Understanding where zoledronic acid fits helps you and your physician choose the best option for both clinical and financial outcomes.

Alendronate (Fosamax). Tier 1 generic. No PA required. Copay: $0 to $15/month. First-line on UHC formularies. Weekly oral dosing. GI side effects limit adherence; real-world persistence at 12 months is only about 50% 10.

Denosumab (Prolia). Tier 3 specialty. PA required. Copay: $200 to $600 per injection (every 6 months). No step therapy required on some UHC plans. Rebound vertebral fractures upon discontinuation are a documented risk 11.

Teriparatide (Forteo) and abaloparatide (Tymlos). Tier 4 or specialty tier. PA required with step therapy. High cost ($2,000 to $3,500/month). Reserved for severe osteoporosis or failure of antiresorptive therapy.

Romosozumab (Evenity). Tier 4 specialty. PA required. 12-month course costs approximately $22,000 to $28,000. UHC typically requires documented very high fracture risk and failure of at least one prior agent.

Zoledronic acid's once-yearly IV dosing gives it a significant adherence advantage. In the HORIZON trial extension, patients who received three annual infusions maintained bone density gains for up to 6 years after the last dose 12. No oral bisphosphonate offers that kind of dosing simplicity or post-treatment durability.

Getting Reclast Approved: A Step-by-Step Checklist

For patients and prescribers working through the UHC coverage process, this sequence minimizes delays:

1. Confirm your plan's formulary tier for zoledronic acid (brand and generic) through the UHC member portal or by calling the number on your insurance card.
2. Obtain a DXA scan within the past 24 months.
3. Document oral bisphosphonate history (drug name, dose, duration, reason for discontinuation).
4. Check labs: serum calcium, 25-OH vitamin D (replete to ≥30 ng/mL before infusion), and eGFR (must be ≥35 mL/min).
5. Have your prescriber submit the PA with all documentation attached. Include ICD-10 codes: M81.0 (age-related osteoporosis without fracture), M80.0 (age-related osteoporosis with fracture), or M88.9 (Paget disease).
6. If denied, file Level 1 appeal within 180 days with a letter of medical necessity, guideline references, and updated imaging or labs.
7. If Level 1 is denied, proceed to Level 2 within 60 days.
8. If Level 2 is denied, request external IRO review.

Infusion site selection also affects cost. Hospital outpatient departments bill facility fees that can double the total charge. Ask your physician about office-based infusion or independent infusion centers, which typically bill only the drug cost and an administration fee (CPT 96365 for the first hour, 96366 for each additional hour). A 15-minute zoledronic acid infusion at an independent center often costs 40% to 60% less than the same infusion at a hospital outpatient facility.